FDA Approves Rylaze as Alternative for Patients with ALL and Lymphoblastic Lymphoma

New FDA approval means that pediatric and adult patients with acute lymphoblastic leukemia (ALL) and lympoblastic lymphoma who are allergic to the E. coli-derived asparaginase products, are now able to be treated with asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regiment.

Read more: https://www.oncnursingnews.com/view/fda-approves-rylaze-as-alternative-for-patients-with-all-and-lymphoblastic-lymphoma